KLP Kapitalforvaltning AS Invests $158,000 in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

KLP Kapitalforvaltning AS purchased a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 8,000 shares of the company’s stock, valued at approximately $158,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KNSA. Teacher Retirement System of Texas boosted its position in shares of Kiniksa Pharmaceuticals by 7.1% during the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock worth $215,000 after purchasing an additional 719 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Kiniksa Pharmaceuticals by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock valued at $174,000 after purchasing an additional 1,004 shares during the period. Franklin Resources Inc. boosted its holdings in Kiniksa Pharmaceuticals by 1.7% during the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock worth $1,798,000 after buying an additional 1,100 shares in the last quarter. New York State Common Retirement Fund grew its position in Kiniksa Pharmaceuticals by 12.4% during the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company’s stock worth $302,000 after buying an additional 1,680 shares during the period. Finally, Quarry LP acquired a new position in Kiniksa Pharmaceuticals during the third quarter worth about $50,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Stock Down 3.9 %

Shares of NASDAQ KNSA opened at $19.48 on Wednesday. The stock has a market capitalization of $1.42 billion, a PE ratio of -139.13 and a beta of 0.31. The firm has a fifty day moving average of $20.96 and a 200-day moving average of $21.74. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The firm had revenue of $122.50 million for the quarter, compared to analysts’ expectations of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s revenue was up 46.9% on a year-over-year basis. During the same period last year, the firm posted $0.35 EPS. Equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,051 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the transaction, the chief accounting officer now directly owns 26,528 shares of the company’s stock, valued at $595,553.60. This represents a 25.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Mark Ragosa sold 11,464 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $23.10, for a total value of $264,818.40. Following the transaction, the chief financial officer now owns 23,382 shares of the company’s stock, valued at approximately $540,124.20. This trade represents a 32.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 93,766 shares of company stock worth $2,011,735 in the last quarter. 54.57% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

KNSA has been the topic of several recent research reports. Wedbush reiterated an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 price target on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals has an average rating of “Buy” and an average price target of $37.17.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.